HRS-1358 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Trial primary completion date: Dec 2024 ➔ Jun 2025

Monotherapy • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=300 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor

Hengrui Medicine’s 4 new cancer drugs approved for clinical trials, 3 of which are protein degraders [Google translation] (Sina Corp) - "On October 18, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) announced that Hengrui Medicine...has 4 new cancer drugs approved for multiple new clinical trial implied licenses. One of them is an anti-CTLA-4 monoclonal antibody new drug, and the other three are Class 1 new drugs for protein degradation therapy. These new drugs have been approved for clinical research on the treatment of malignant tumors with dual or triple drug combination therapy , which means that Hengrui Medicine has an important exploration direction in cancer treatment."

New trial • Oncology • Solid Tumor

Hengrui Medicine’s innovative drug HRS-2189 tablets for combination therapy of advanced solid tumors approved for clinical trials [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Hengrui Medicine...received the 'Notice of Approval for Drug Clinical Trial' approved and issued by the National Medical Products Administration, approving the company to conduct an open, multicenter Phase IB/II clinical study on the safety, tolerability, pharmacokinetics and preliminary efficacy of HRS-2189 combined with fulvestrant with or without HRS-6209, or with HRS-6209 and HRS-8080, or with HRS-6209 and HRS-1358, or with abiraterone acetate tablets (II) and prednisone tablets, or with HRS-5041, or with adebelimumab with or without SHR - 8068 with or without chemotherapy, or with adebelimumab and bevacizumab in subjects with advanced unresectable or metastatic solid tumors."

Trial status • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=300 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=528 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Enrolling by invitation ➔ Recruiting | Trial primary completion date: Jun 2024 ➔ Dec 2024

Enrollment status • Metastases • Monotherapy • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=528 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor

Hengrui Medicine's three innovative cancer drugs were approved for clinical trials! Two of them are protein degraders [Google translation] (Sina Corp) - "Hengrui Medicine announced on the evening of July 26 that the company and its subsidiary Shandong Shengdi Pharmaceutical's HRS-1358 tablets, HRS-8080 tablets, and HRS-6209 capsules have received drug clinical trial approval notices issued by the China National Medical Products Administration (NMPA) and will conduct clinical trials in the near future. The approved clinical indications are: HRS-6209 combined with HRS-1358 or HRS-8080 or aromatase inhibitors or fulvestrant for the treatment of breast cancer."

New trial • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=102 | Enrolling by invitation | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Metastases • Monotherapy • Breast Cancer • Oncology • Solid Tumor

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer (clinicaltrials.gov) - P1 | N=102 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

Monotherapy • New P1 trial • Breast Cancer • Oncology • Solid Tumor